Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic psychedelic Use : An Online Survey Albert Garcia-Romeu, Alan K. Davis, Earth Erowid, Fire Erowid, Roland R. Griffiths and Matthew W. Johnson Frontiers in Psychiatry, 2020, Vol 10, Article 955. Doi : 10.3389/fpsyt.2019.00955 Background : Observational data and preliminary studies suggest serotonin 2A agonist psychedelics may hold potential in treating a variety of substance use disorders (SUDs), including opioid use disorder (OUD). Aims : The study aim was to describe and analyze self-reported cases in which naturalistic psychedelic use was followed by cessation or reduction in other substance use. Methods : An anonymous online survey of [...]
Lire la suiteMicrodosing psychedelics: Demographics, practices, and psychiatric comorbidities Daniel Rosenbaum, Cory Weissman, Thomas Anderson, Rotem Petranker, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke Journal of Psychopharmacology, 2020, 1-11. doi.org/10.1177/0269881120908004 Abstract Rationale : Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives : To examine the practices and demographics of a population of psychedelic microdosers – including their psychiatric diagnoses, prescription medications, and recreational substance use patterns – to develop a foundation [...]
Lire la suiteCannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Case Report Clarissa Laczkovics · Oswald D. Kothgassner · Anna Felnhofer · Claudia M. Klier Neuropsychiatrie, 2020, 4 p. Doi : 10.1007/s40211-020-00334-0 Summary In this report, we present a case of a 16,9- year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder. We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants. CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and [...]
Lire la suiteCannabis Use in Adolescence : A Review of Neuroimaging Findings Yann Chye, Erynn Christensen & Murat Yücel Journal of Dual Diagnosis, 2019 Doi : 10.1080/15504263.2019.1636171 ABSTRACT Objective : Shifting policies and widespread acceptance of cannabis for medical and/or recreational purposes have fueled worries of increased cannabis initiation and use in adolescents. In particular, the adolescent period is thought to be associated with an increased susceptibility to the potential harms of repeated cannabis use, due to being a critical period for neuromaturational events in the brain. This review investigates the neuroimaging evidence of brain harms attributable to adolescent cannabis use. Methods : PubMed and Scopus searches were [...]
Lire la suiteEndocannabinoid-mediated synaptic plasticity and substance use disorders E. Fernandez-Espejo, L. Nunez-Dominguez Neurologia, 2019 Copyright © 2019 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved. doi : 10.1016/j.nrl.2018.12.004 Abstract Drugs impact brain reward circuits, causing dependence and addiction, in a condition currently described as substance use disorders. Mechanisms of synaptic plasticity in these circuits are crucial in the development of addictive behaviour, and endocannabinoids, particularly anandamide and 2-arachidonyl-glycerol, participate in normal neuroplasticity. Substance use disorders are known to be associated with disruption of endocannabinoid-mediated synaptic plasticity, among other phenomena. Endocannabinoids mediate neuroplasticity in the short and the long term. In the short term, [...]
Lire la suitePrevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, 1, 133-138. Doi : 10.1089/can.2017.0006 Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]
Lire la suiteTransdermal Delivery of Cannabidiol Attenuates Binge Alcohol- Induced Neurodegeneration in a Rodent Model of an Alcohol Use Disorder Daniel J. Liput, Dana C. Hammell, Audra L. Stinchcomb, and Kimberly Nixon Pharmacology, Biochemistry and Behavior, 2013, 111, 120–127. doi : 10.1016/j.pbb.2013.08.013 Abstract Excessive alcohol consumption, characteristic of alcohol use disorders, results in neurodegeneration and behavioral and cognitive impairments that are hypothesized to contribute to the chronic and relapsing nature of alcoholism. Therefore, the current study aimed to advance the preclinical development of transdermal delivery of cannabidiol (CBD) for the treatment of alcohol-induced neurodegeneration. In experiment 1, 1.0%, 2.5% and 5.0% CBD gels were evaluated for neuroprotection. [...]
Lire la suiteEfficacy of Ketamine in the Treatment of Substance Use Disorders : A Systematic Review Jennifer L. Jones, Camilo F. Mateus, Robert J. Malcolm, Kathleen T. Brad and Sudie E. Back Frontiers in Psychiatry, 2018, 1-10. doi : 10.3389/fpsyt.2018.00277 Abstract Background : Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse. Ketamine is a potent N-methyl-D-aspartate (NMDA) glutamatergic receptor antagonist which has been found to be effective in the treatment of severe depression. Here we review the literature on the efficacy of ketamine in [...]
Lire la suite